Transamniotic Delivery of Hematopoietic Stem Cells Genetically Modified to Carry a Human Hemoglobin Subunit Beta Gene (HBB) in a Healthy Rodent Model
Topic overview
This preclinical study evaluates transamniotic delivery of genetically modified hematopoietic stem cells carrying the human hemoglobin beta gene in a rat model. The research explores a minimally invasive fetal intervention approach that could potentially treat hemoglobinopathies like sickle cell disease before birth.
Key takeaways
- Transamniotic stem cell therapy (TRASCET) offers a minimally invasive route for delivering genetically modified HSCs to the fetus.
- Study tested delivery of hematopoietic stem cells carrying human hemoglobin subunit beta gene (hHBB) via amniotic fluid in rats.
- TRASCET may provide an alternative to direct intravascular fetal injection for gene therapy in hemoglobinopathies like sickle cell disease.
- Healthy syngeneic rat model used to establish proof-of-concept for transamniotic delivery of gene-modified stem cells.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Transamniotic Delivery of Hematopoietic Stem Cells Genetically Modified to Carry a Human Hemoglobin Subunit Beta Gene (HBB) in a Healthy Rodent Model. GlobalCastMD Medical Library. 2024-12-21. https://dev.library.globalcastmd.com/article/9556?via_space=staycurrentmd
Comments